B+
Bull case
0%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
SLDB
Solid BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The best case is that SGT-003 keeps showing differentiated tolerability and biomarker/functional support, Phase 3 dosing starts on time, and FDA discussions make an accelerated route look viable; combined with runway into H1 2028, that can support a sharper rerating from a depressed base.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.5.
What can break
Competitive pressure from Sarepta, REGENXBIO, and other Duchenne programs could compress SLDB’s differentiation narrative.
Momentum
87
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.60 · Bull $11.50 · Bear $5.50Analysis 2026-04-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.67
Why
Momentum87 · Δ7d +3.7
Value41 · Δ7d 0.0
Sentiment51 · Δ7d +4.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +4.5.
Contradictions & invalidation
- • Competitive pressure from Sarepta, REGENXBIO, and other Duchenne programs could compress SLDB’s differentiation narrative.
- • Despite improved runway, future dilution risk remains meaningful if development timelines extend or multiple programs scale at once.
- • The bear case is that Solid still has mainly interim evidence, faces entrenched Duchenne competition from both approved and late-stage peers, and could suffer materially if Phase 3 startup slips or FDA feedback on accelerated approval is less supportive than hoped.
Catalyst clock
2026-04-30
First Phase 3 IMPACT DUCHENNE dosing
Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
+13.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
51
62% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
-8.2
Why this grade
Composite grade D. Momentum 86.7 / Value 41.2 / Sentiment 50.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-17. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$8.60
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$975.75M
Beta
2.68
Shares Out
107.23M
P/E (TTM) · Derived
-4.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.27
Rev YoY
-100.0%
EPS YoY
-9.1%
Gross Margin
+55.0%
Op Margin
-
Net Debt
-$167.91M
Current Ratio
13.82
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data